BJL
ALDX icon

Brighton Jones LLC’s Aldeyra Therapeutics ALDX Stock Holding History

Brighton Jones LLC’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4K Sell
16,144
-6,055
-27% -$10.4K ﹤0.01% 1383
2026
Q1 		$37.5K Buy
+22,199
New +$97.3K ﹤0.01% 1174
2025
Q4 		– Sell
-19,945
Closed -$104K – 86
2025
Q3 		$104K Buy
19,945
+2,046
+11% +$10.7K ﹤0.01% 990
2025
Q2 		$68.6K Buy
+17,899
New +$46.3K ﹤0.01% 901

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Brighton Jones LLC's ALDX Position: Q2 2026 in Review

Brighton Jones LLC reduced its Aldeyra Therapeutics (ALDX) stake by 27% in Q2 2026, selling an estimated $10.4K and leaving 16,144 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

Brighton Jones LLC first reported a position in ALDX in Q2 2025 and has held it in 4 quarters since. The position peaked at $104K in Q3 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Brighton Jones LLC held 16,144 shares of Aldeyra Therapeutics worth $34.4K as of Q2 2026.
  • Brighton Jones LLC sold 6,055 Aldeyra Therapeutics shares in Q2 2026, an estimated $10.4K.
  • Aldeyra Therapeutics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1383 holding.
  • Brighton Jones LLC first reported a position in Aldeyra Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Brighton Jones LLC's Aldeyra Therapeutics position peaked at $104K in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.